ACT I early feasibility study of the Voyager Ark vascular access device
The results demonstrated the Ark could be used successfully in End-Stage Renal Disease (ESRD) patients undergoing hemodialysis three times a week. These results suggest preliminary safety and efficacy of the Ark as a promising cannulation tool for dialysis vascular access and warrant further exploration of long-term safety and effectiveness through a pivotal clinical study involving a larger population and extended follow-up.
Authors
- Stephen Hohmann
- Abhishek Rajendra Potnis (ORCID: https://orcid.org/0000-0003-2741-3350)
- Alan Glowczwski
- John Ross (ORCID: https://orcid.org/0000-0003-2177-3961)
- April Lovelady (ORCID: https://orcid.org/0000-0002-1079-9325)
- Justin Glowczwski
- Ashok Gowda
Institutions
- Voyager Therapeutics (United States) (US)
- Biotex (United States) (US)
- Regional Medical Center (US)
- Baylor Scott & White Health (US)
- Texas A&M University (US)
Publication Details
- Journal
- The Journal of Vascular Access
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1177/11297298241302887
- Primary Topic
- Central Venous Catheters and Hemodialysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00